Company / EPS (Basic)
ResMed EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$6.12
FY2025
5-year range
$2.83 / $6.12
FY2021-FY2025
Trend
+14.6%
vs FY2024
Sector context
#26 of 160
Health Care
What the data says
ResMed's eps (basic) of $6.12 is higher than 84% of companies in the Health Care sector (FY2025). EPS (Basic) has fluctuated over the past 10 years, ranging from $2.21 in FY2020 to $6.12 in FY2025.
Based on SEC 10-K filings.
6.12 in FY2025 with a 5-year CAGR of +22.6%. Top quartile in the Health Care sector.
Improved from $3.27 to $6.12 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- +12.4%
- 5-Year CAGR
- +22.6%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 160This company $6.12 Sector average $1.66
▼
+269.5% above sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 14.6% year-over-year.
- Ranks #26 out of 160 companies in the Health Care sector.
- Lowest eps (basic) in the period was in FY2020.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.12 | +14.6% |
| FY2024 | $5.34 | +63.3% |
| FY2023 | $3.27 | -24.1% |
| FY2022 | $4.31 | +52.3% |
| FY2021 | $2.83 | +28.1% |
| FY2020 | $2.21 | -8.7% |
| FY2019 | $2.42 | -3.6% |
| FY2018 | $2.51 | +0.0% |
| FY2017 | $2.51 | +2.9% |
| FY2016 | $2.44 | +13.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026